|
AU2005228950B2
(en)
*
|
2004-03-23 |
2012-02-02 |
Genentech, Inc. |
Azabicyclo-octane inhibitors of IAP
|
|
ES2475207T3
(es)
|
2004-07-15 |
2014-07-10 |
Tetralogic Pharmaceuticals Corporation |
Compuestos de unión a IAP
|
|
DK1836201T4
(da)
|
2004-12-20 |
2013-11-11 |
Genentech Inc |
Pyrrolidininhibitorer af IAP.
|
|
MX2007010371A
(es)
*
|
2005-02-25 |
2008-01-11 |
Tetralogic Pharmaceuticals |
Inhibidores dimericos iap.
|
|
JP4954983B2
(ja)
|
2005-05-18 |
2012-06-20 |
ファーマサイエンス・インコーポレイテッド |
Ｂｉｒドメイン結合化合物
|
|
CA2617642A1
(en)
*
|
2005-08-09 |
2007-02-22 |
Tetralogic Pharmaceuticals Corporation |
Treatment of proliferative disorders
|
|
US20100256046A1
(en)
*
|
2009-04-03 |
2010-10-07 |
Tetralogic Pharmaceuticals Corporation |
Treatment of proliferative disorders
|
|
WO2007048224A1
(en)
|
2005-10-25 |
2007-05-03 |
Aegera Therapeutics Inc. |
Iap bir domain binding compounds
|
|
KR20080080131A
(ko)
|
2005-12-20 |
2008-09-02 |
노파르티스 아게 |
Ｉａｐ-억제제와 탁산의 조합물
|
|
TWI504597B
(zh)
|
2006-03-16 |
2015-10-21 |
Pharmascience Inc |
結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
|
|
US8202902B2
(en)
|
2006-05-05 |
2012-06-19 |
The Regents Of The University Of Michigan |
Bivalent SMAC mimetics and the uses thereof
|
|
NZ572531A
(en)
*
|
2006-05-05 |
2011-09-30 |
Univ Michigan |
Bivalent smac mimetics and the uses thereof
|
|
CN101535300B
(zh)
|
2006-05-16 |
2014-05-28 |
埃格拉医疗公司 |
Iap bir域结合化合物
|
|
WO2008014229A2
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
WO2008014240A2
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
JP5452223B2
(ja)
|
2006-07-24 |
2014-03-26 |
テトラロジック ファーマシューティカルズ コーポレーション |
Ｉａｐ阻害剤
|
|
US20100056495A1
(en)
*
|
2006-07-24 |
2010-03-04 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
MX2009000824A
(es)
*
|
2006-07-24 |
2009-02-04 |
Tetralogic Pharmaceuticals Cor |
Antagonistas dimericos de las proteinas inhibidoras de la apoptosis.
|
|
JP5454943B2
(ja)
|
2007-04-12 |
2014-03-26 |
ジョイアント ファーマスーティカルズ、インク． |
抗癌剤として有用なｓｍａｃ模倣二量体及び三量体
|
|
WO2008134679A1
(en)
*
|
2007-04-30 |
2008-11-06 |
Genentech, Inc. |
Inhibitors of iap
|
|
JP2010528587A
(ja)
*
|
2007-05-07 |
2010-08-26 |
テトラロジック ファーマシューティカルズ コーポレーション |
アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてＴＮＦα遺伝子の発現を用いる方法
|
|
CN102099035A
(zh)
|
2008-05-16 |
2011-06-15 |
诺瓦提斯公司 |
Iap抑制剂的免疫调节
|
|
JP2011529962A
(ja)
*
|
2008-08-02 |
2011-12-15 |
ジェネンテック， インコーポレイテッド |
Ｉａｐのインヒビター
|
|
WO2010033531A1
(en)
|
2008-09-17 |
2010-03-25 |
Tetralogic Pharmaceuticals Corp. |
Iap inhibitors
|
|
US20100116955A1
(en)
*
|
2008-11-13 |
2010-05-13 |
Hayes Richard J |
Towel holder and method of manufacture
|
|
US8481495B2
(en)
*
|
2009-05-28 |
2013-07-09 |
Tetralogic Pharmaceuticals Corporation |
IAP inhibitors
|
|
AU2010254056A1
(en)
*
|
2009-05-28 |
2011-12-15 |
Tetralogic Pharmaceuticals Corp. |
IAP inhibitors
|
|
US8283372B2
(en)
|
2009-07-02 |
2012-10-09 |
Tetralogic Pharmaceuticals Corp. |
2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
|
|
US20110034469A1
(en)
|
2009-08-04 |
2011-02-10 |
Takeda Pharmaceutical Company Limited |
Heterocyclic Compound
|
|
EP2478358A1
(en)
|
2009-09-18 |
2012-07-25 |
Novartis AG |
Biomarkers for iap inhibitor compounds
|
|
US8551955B2
(en)
|
2009-10-28 |
2013-10-08 |
Joyant Pharmaceuticals, Inc. |
Dimeric Smac mimetics
|
|
US9284350B2
(en)
|
2010-02-12 |
2016-03-15 |
Pharmascience Inc. |
IAP BIR domain binding compounds
|
|
US20140243276A1
(en)
|
2011-09-30 |
2014-08-28 |
Tetralogic Pharmaceuticals Corporation |
Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
|
|
US9353419B2
(en)
|
2012-05-04 |
2016-05-31 |
Novartis Ag |
Biomarkers for IAP inhibitor therapy
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
ES2701051T3
(es)
|
2013-03-15 |
2019-02-20 |
Novartis Ag |
Conjugados de anticuerpo-fármaco
|
|
KR20160030099A
(ko)
|
2013-06-25 |
2016-03-16 |
더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 |
세포내 감염의 치료 방법
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
JP6768522B2
(ja)
|
2014-06-04 |
2020-10-14 |
サンフォード−バーンハム メディカル リサーチ インスティテュート |
Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用
|
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
|
MA40513A
(fr)
|
2014-08-12 |
2017-06-21 |
Novartis Ag |
Conjugués médicament-anticorps anti-cdh6
|
|
WO2016079527A1
(en)
|
2014-11-19 |
2016-05-26 |
Tetralogic Birinapant Uk Ltd |
Combination therapy
|
|
WO2016097773A1
(en)
|
2014-12-19 |
2016-06-23 |
Children's Cancer Institute |
Therapeutic iap antagonists for treating proliferative disorders
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
JP6817962B2
(ja)
|
2015-01-20 |
2021-01-20 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
ターゲティングされたアンドロゲン受容体分解のための化合物および方法
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
|
US10772962B2
(en)
|
2015-08-19 |
2020-09-15 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
EP3368092B9
(en)
|
2015-10-29 |
2020-07-29 |
Novartis AG |
Antibody conjugates comprising toll-like receptor agonist
|
|
MX2019005007A
(es)
|
2016-11-01 |
2019-07-18 |
Arvinas Inc |
Protac dirigidos a la proteína tau y métodos asociados de uso.
|
|
BR112019011200B1
(pt)
|
2016-12-01 |
2021-12-28 |
Arvinas Operations, Inc |
Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio
|
|
KR20250117470A
(ko)
|
2016-12-23 |
2025-08-04 |
아비나스 오퍼레이션스, 인코포레이티드 |
급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
|
|
JP2020505327A
(ja)
|
2016-12-23 |
2020-02-20 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法
|
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
BR112019015312A2
(pt)
|
2017-01-26 |
2020-03-10 |
Arvinas Operations, Inc. |
Moduladores da proteólise pelo receptor de estrogênio e métodos de uso associados
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
WO2018163051A1
(en)
|
2017-03-06 |
2018-09-13 |
Novartis Ag |
Methods of treatment of cancer with reduced ubb expression
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
MY206158A
(en)
|
2017-05-24 |
2024-12-02 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
WO2018215938A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use
|
|
EP3710443A1
(en)
|
2017-11-17 |
2020-09-23 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
|
EP3765026A4
(en)
|
2018-03-10 |
2021-12-22 |
Yale University |
BTK PROTEOLYSIS MODULATORS AND METHODS FOR USE
|
|
WO2019195609A2
(en)
|
2018-04-04 |
2019-10-10 |
Arvinas Operations, Inc. |
Modulators of proteolysis and associated methods of use
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
BR122022012697B1
(pt)
|
2018-07-10 |
2023-04-04 |
Novartis Ag |
Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
|
|
WO2020023851A1
(en)
|
2018-07-26 |
2020-01-30 |
Yale University |
Bifunctional substitued pyrimidines as modulators of fak proteolyse
|
|
JP7297053B2
(ja)
|
2018-08-20 |
2023-06-23 |
アルビナス・オペレーションズ・インコーポレイテッド |
神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
|
|
IL281188B2
(en)
|
2018-09-07 |
2025-08-01 |
Arvinas Operations Inc |
Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
|
|
US20230053449A1
(en)
|
2018-10-31 |
2023-02-23 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
|
KR20210106437A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
|
|
KR20210107731A
(ko)
|
2018-12-21 |
2021-09-01 |
노파르티스 아게 |
Pmel17에 대한 항체 및 이의 접합체
|
|
CN113490528B
(zh)
|
2019-02-15 |
2024-12-03 |
诺华股份有限公司 |
3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
CA3123519A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
EP3999182A1
(en)
|
2019-07-17 |
2022-05-25 |
Arvinas Operations, Inc. |
Tau-protein targeting compounds and associated methods of use
|
|
EP4007592A1
(en)
|
2019-08-02 |
2022-06-08 |
LanthioPep B.V. |
Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer
|
|
KR20220054347A
(ko)
|
2019-08-26 |
2022-05-02 |
아비나스 오퍼레이션스, 인코포레이티드 |
에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
|
|
BR112022011902A2
(pt)
|
2019-12-20 |
2022-09-06 |
Novartis Ag |
Terapias de combinação
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
JP2023529211A
(ja)
|
2020-06-11 |
2023-07-07 |
ノバルティス アーゲー |
Ｚｂｔｂ３２阻害剤及びその使用
|
|
KR20230027056A
(ko)
|
2020-06-23 |
2023-02-27 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
|
|
JP7819176B2
(ja)
|
2020-08-03 |
2026-02-24 |
ノバルティス アーゲー |
ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
|
|
WO2022047145A1
(en)
|
2020-08-28 |
2022-03-03 |
Arvinas Operations, Inc. |
Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
|
|
WO2022056368A1
(en)
|
2020-09-14 |
2022-03-17 |
Arvinas Operations, Inc. |
Crystalline forms of a compound for the targeted degradation of estrogen receptor
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
BR112023021475A2
(pt)
|
2021-04-16 |
2023-12-19 |
Novartis Ag |
Conjugados anticorpo-fármaco e métodos para produzir os mesmos
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
AU2023314354A1
(en)
|
2022-07-26 |
2024-11-21 |
Novartis Ag |
Crystalline forms of an akr1c3 dependent kars inhibitor
|
|
WO2024054591A1
(en)
|
2022-09-07 |
2024-03-14 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|
|
US12448399B2
(en)
|
2023-01-26 |
2025-10-21 |
Arvinas Operations, Inc. |
Cereblon-based KRAS degrading PROTACs and uses related thereto
|